Karley Whelan, Mairead Dillon, Kyle C Strickland, Bhavana Pothuri, Victoria Bae-Jump, Lindsay E Borden, Premal H Thaker, Paulina Haight, Rebecca C Arend, Emily Ko, Amanda L Jackson, Bradley R Corr, Martins Ayoola-Adeola, Jason D Wright, Sarah Podwika, Carson Smitherman, Samantha Thomas, Michelle Lightfoot, Meredith Newton, Christina Washington, Mary Mullen, Casey Cosgrove, Alfonsus Adrian Hadikusumo Harsono, Kristina Powell, Thomas J Herzog, Ritu Salani, Angeles Alvarez Secord
OBJECTIVE: This multi-center cohort study assessed associations between race, TP53 mutations, p53 expression, and histology to investigate racial survival disparities in endometrial cancer (EC). METHODS: Black and White patients with advanced or recurrent EC with Next Generation Sequencing data in the Endometrial Cancer Molecularly Targeted Therapy Consortium database were identified. Clinicopathologic and treatment variables were summarized by race and compared...
September 23, 2023: Gynecologic Oncology
Mayumi Kobayashi-Kato, Erisa Fujii, Yuka Asami, Yuka Ahiko, Kengo Hiranuma, Yasuhisa Terao, Koji Matsumoto, Mitsuya Ishikawa, Takashi Kohno, Tomoyasu Kato, Kouya Shiraishi, Hiroshi Yoshida
OBJECTIVES: Molecular classification was introduced in endometrial cancer staging following the transition of the International Federation of Gynecology and Obstetrics (FIGO) 2008 to FIGO2023. In the early stages, p53 abnormal endometrial carcinoma with myometrial involvement was upstaged to stage IICm , in addition to the downstaging of POLE mutation endometrial cancer to stage IAm . This study compared the goodness of fit and discriminatory ability of FIGO2008, FIGO2023 without molecular classification (FIGO2023), and FIGO2023 with molecular classification (FIGO2023m ); no study has been externally validated to date...
September 23, 2023: Gynecologic Oncology
William A Zammarrelli, Weining Ma, Kevin Espino, Sushmita Gordhandas, Effi Yeoshoua, Sarah Ehmann, Qin Zhou, Alexia Iasonos, Nadeem R Abu-Rustum, Carol Aghajanian, Angela K Green, Maria M Rubinstein, Vicky Makker
OBJECTIVE: To evaluate adverse events (AEs) of combination lenvatinib plus pembrolizumab for the treatment of recurrent endometrial cancer (EC) and to assess outcomes by lenvatinib starting dose. METHODS: We retrospectively reviewed patients with recurrent EC treated with lenvatinib plus pembrolizumab at our institution between 10/1/2019-11/30/2021. Starting dose of lenvatinib was defined as standard (20 mg) or reduced (10 mg/14 mg). AEs were manually extracted through chart review and graded using Common Terminology Criteria for Adverse Events (CTCAE) version 5...
September 23, 2023: Gynecologic Oncology
Teresa K L Boitano, Austin Gardner, Daniel I Chu, Charles A Leath, J Michael Straughn, Haller J Smith
OBJECTIVE: To evaluate the impact of a mobile health patient engagement technology (PET) on postoperative outcomes in gynecologic oncology patients. METHODS: All gynecologic oncology patients undergoing laparotomy on an enhanced recovery program (ERP) were approached from July 2019 to May 2021 to enroll in a PET, which can be accessed by computer, tablet, or smart phone. This platform provides enhanced pre- and postoperative patient education and remote patient monitoring...
September 22, 2023: Gynecologic Oncology
Paulina J Haight, Quinn Kistenfeger, Courtney J Riedinger, Wafa Khadraoui, Floor J Backes, Kristin L Bixel, Larry J Copeland, David E Cohn, Casey M Cosgrove, David M O'Malley, Christa I Nagel, Daniel J Spakowicz, Laura M Chambers
OBJECTIVE: We sought to assess the impact of antibiotic (ABX) and proton-pump inhibitor (PPI) use on progression-free (PFS) and overall survival (OS) in patients treated with adjuvant platinum-based chemotherapy (PC) for endometrial cancer (EC). METHODS: A retrospective, single-institution cohort study of EC patients treated with ≥four cycles of adjuvant PC following surgical staging from 2014 to 2020. Demographics and clinicopathologic features, including ABX and PPI use, were compared using χ2 and Fisher's exact tests...
September 21, 2023: Gynecologic Oncology
Fei Chen, Guo-Nan Zhang, Wei Lei, Shu-Guang Zhou, Ying Zhang, Lin Liu, Ying Jia, Rong-Kai Xie, Xiu-Fang Tian, Jie Guo, Yue-Bo Yang, Xue-Feng Wang, Xiao-Mei Wu, Qi-Jian Sun, Xu Zhou, Yang Lin, You-Zhong Zhang, Jun-Qi Ma, Yu-Xiu Liu, Yi-Fan Cheng, Jian-Cui Chen, Quan-Xin Qu, Dong-Mei Du, Gui-Yu Wang, Sheng Wang, Yu-Li Ling, Dai-Fei Wu, Chun-Fa Zhang, Jing-He Lang
BACKGROUND: We previously reported that REBACIN effectively eliminates persistent high-risk human papillomavirus (hrHPV) infection. Here, we conducted a prospective multicenter cohort study to evaluate the safety and effectiveness of REBACIN, taking into account factors such as specific hrHPV subtype and patient's age. METHODS: According to inclusion/exclusion criteria and participant willingness, 3252 patients were divided into REBACIN group while 249 patients into control group...
September 19, 2023: Gynecologic Oncology
Kristin A Black, Gregg Nelson, Natalie Goucher, Joshua Foley, Sophia Pin, Michael Chong, Sunita Ghosh, Steven P Bisch
OBJECTIVES: To characterize the effect of transversus abdominis plane (TAP) blocks on post-operative outcomes in patients undergoing laparotomy for gynecologic malignancy. METHODS: This retrospective cohort study assessed patients undergoing laparotomy in 2016-2017 and 2020 in Alberta, Canada. The primary outcome was opioid consumption in oral morphine milligram equivalent (MME). Secondary outcomes included maximum pain scores, length of stay, and patient-controlled analgesia (PCA) use...
September 18, 2023: Gynecologic Oncology
T R Hall, J E MacDonald, K M Bylinowski, E A Alvarez, M M Hardesty, J A Smith
OBJECTIVE: The goal of this practice statement is to help members and their multidisciplinary teams recognize infusion reactions and hypersensitivity reactions in the clinical setting. It will provide recommendations to help guide response to reactions and desensitization when appropriate, to promote safe use of chemotherapeutic agents among all providers in the delivery process. METHODS: A multi-disciplinary team of healthcare professionals from the Society of Gynecologic Oncology Education Committee collaborated to review peer reviewed literature and guidelines to develop a practice statement on the management of chemotherapy hypersensitivity reactions and desensitization regimens...
September 15, 2023: Gynecologic Oncology
Leah A Marsh, Teresa H Kim, Mingyan Zhang, Kari Kubalanza, Charisse Liz Treece, Dana Chase, Sanaz Memarzadeh, Ritu Salani, Beth Karlan, Jianyu Rao, Gottfried E Konecny
OBJECTIVE: We aimed to validate whether pathologic response (pR) to neoadjuvant chemotherapy (NACT) using a three-tier chemotherapy response score (CRS) is associated with clinical outcome in ovarian cancer (OC) and could be used as surrogate marker for survival. METHODS: We conducted a retrospective study of OC patients with FIGO stage III/IV disease who received NACT and graded response as no or minimal (CRS 1), partial (CRS 2), or complete/near-complete (CRS 3) pR using tissue specimens obtained from omentum...
September 14, 2023: Gynecologic Oncology
Alexi A Wright, Hanneke Poort, Anna Tavormina, Sarah J Schmiege, Ursula A Matulonis, Susana M Campos, Joyce F Liu, Elizabeth T Slivjak, Anna L Gilmour, Julia M Salinger, Ashley F Haggerty, Joanna J Arch
OBJECTIVE: Poly(ADP-ribose) polymerase inhibitors (PARPi) have dramatically changed treatment for advanced ovarian cancer, but nearly half of patients experience significant fatigue. We conducted a two-site pilot randomized trial to evaluate the feasibility, acceptability, and preliminary efficacy of a brief, acceptance-based telehealth intervention (REVITALIZE) designed to reduce fatigue interference in patients on PARPi. METHODS: From June 2021 to April 2022, 44 participants were randomized 1:1 to REVITALIZE (6 weekly one-on-one sessions+booster) or enhanced usual care...
September 12, 2023: Gynecologic Oncology
Nuria Agustí, David Viveros-Carreño, Nathalia Mora-Soto, Pedro T Ramírez, Alejandro Rauh-Hain, Chi-Fang Wu, Juliana Rodríguez, Carlos Fernando Grillo-Ardila, Catherin Salazar, Kirsten Jorgensen, Blanca Segarra-Vidal, Enrique Chacón, Alexander Melamed, René Pareja
OBJECTIVE: To assess the diagnostic accuracy of intraoperative SLN frozen section analysis compared with ultrastaging in patients with early-stage cervical cancer. METHODS: A systematic literature review was conducted following the PRISMA checklist. MEDLINE (via Ovid), Embase, and the Cochrane Central Register of Controlled Trials were searched from inception until February 2023. The inclusion criteria were patients with early-stage cervical cancer (2018 FIGO stage I-II), consisting of the histological subtype squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma (≥90% of the patients in each study), who underwent SLN detection (with any tracer) and intraoperative frozen section followed by SLN ultrastaging...
September 11, 2023: Gynecologic Oncology
Caressa Hui, Maria G Mendoza, Rie von Eyben, Oliver Dorigo, Babak Litkouhi, Malte Renz, Amer Karam, Phoebe M Hammer, Brooke E Howitt, Elizabeth Kidd
OBJECTIVE: The PORTEC-2 update suggested that substantial lymphovascular space invasion (LVSI) and abnormal p53 expression (p53abnl) predict for poorer outcomes and that these patients should be treated with external beam radiation therapy (EBRT). We aim to determine if patients with these risk factors who undergo a lymph node (LN) assessment show similar outcomes. METHODS: We retrospectively reviewed 126 patients with FIGO 2009 stage IA grade 3, stage IB grade 1-2, and stage IIIC (positive LN but no other stage II/III risk factors) endometrioid endometrial cancer who underwent LN assessment...
September 9, 2023: Gynecologic Oncology
Hyo Chun Lee, Jae Won Jeong, Joo Hwan Lee, Sung Hwan Kim, Dong Chun Park, Joo Hee Yoon, Sang Il Kim, Jong Hoon Lee
OBJECTIVE: Radiotherapy dose-escalation using intensity-modulated radiotherapy (IMRT) has been necessary to improve treatment results in cervical cancer. METHODS: This was a phase II prospective clinical trial. 88 patients with FIGO II-IVa cervical cancer were enrolled in a single center. They received high-dose (60 Gy) IMRT with weekly cisplatin to the primary tumor and clinically positive nodes followed by intracavitary radiation. The primary endpoint was 30-month PFS rate (Target; 82%, an increase of 20% compared to GOG 120 trial using standard-dose radiotherapy)...
September 7, 2023: Gynecologic Oncology
Michael D Toboni, Sharon Wu, Alex Farrell, Joanne Xiu, Jennifer R Ribeiro, Matthew J Oberley, Rebecca Arend, Britt K Erickson, Thomas J Herzog, Premal H Thaker, Matthew A Powell
OBJECTIVES: To identify differential survival outcomes and immune checkpoint inhibitor (ICI) response in MLH1 hypermethylated versus MLH1 mutated ("Lynch-like") endometrial tumors and determine whether their molecular profiles can elucidate the differential outcomes. METHODS: 1673 mismatch repair deficient endometrial tumors were analyzed by next-generation sequencing and whole transcriptome sequencing (Caris Life Sciences, Phoenix, AZ). PD-L1, ER, and PR were tested by immunohistochemistry and immune cell infiltrates were calculated using MCP-counter...
September 6, 2023: Gynecologic Oncology
Alberte Hjorth Duus, Guoqiao Zheng, Louise Baandrup, Mette Tuxen Faber, Susanne K Kjær
OBJECTIVE: Recent theories propose that most epithelial ovarian cancer (EOC), depending on histological type, originate from other gynecological tissues and involve the ovary secondarily. According to these theories, any protective effect of salpingectomy and tubal ligation may vary by histological type. The study aim was to examine the association between salpingectomy and tubal ligation, respectively, and risk of EOC, with a focus on associations specific for histological types. METHODS: We identified EOC cases and matching controls in national registries and gathered information on surgical procedures and potential confounders...
September 6, 2023: Gynecologic Oncology
Hyunji Lim, Yiyoung Ju, Se Ik Kim, Jeong Hwan Park, Hee Seung Kim, Hyun Hoon Chung, Jae-Weon Kim, Noh Hyun Park, Yong-Sang Song, Cheol Lee, Maria Lee
OBJECTIVE: In 2014, the World Health Organization introduced a new histologic classification by dividing primary mucinous ovarian carcinoma (PMOC) into two: expansile (ES) or infiltrative subtypes (IS). This study investigated the clinical implications of these histological subtypes on survival outcomes. METHODS: Data from 131 patients with PMOC who underwent primary surgery between 2003 and 2021 were analyzed. The patients baseline characteristics, surgical and pathological information were collected...
September 1, 2023: Gynecologic Oncology
Giulia Spagnol, Matteo Marchetti, Orazio De Tommasi, Amerigo Vitagliano, Francesco Cavallin, Roberto Tozzi, Carlo Saccardi, Marco Noventa
OBJECTIVE: To compare performance of Assessment of Different NEoplasias in the adneXa (ADNEX model), Ovarian-Adnexal Reporting and Data System (O-RADS), Simple Rules Risk (SRR) assessment and the two-step strategy based on the application of Simple Rules (SR) followed by SRR and SR followed by ADNEX in the pre-operative discrimination between benign and malignant adnexal masses (AMs). METHODS: We conducted a retrospective study from January-2018 to December-2021 in which consecutive patients with at AMs were recruited...
September 1, 2023: Gynecologic Oncology
Leslie Andriani, Jinhee Oh, Erin McMinn, Emily Gleason, Nathanael C Koelper, Jesse Chittams, Fiona Simpkins, Emily M Ko
OBJECTIVE: Prior to the COVID-19 pandemic, telehealth visits and remote clinical trial operations (such as local collection of laboratory tests or imaging studies) were underutilized in gynecologic oncology clinical trials. Current literature on these operational changes provides anecdotal experience and expert opinion with few studies describing patient-level safety data. We aimed to evaluate the safety and feasibility of telehealth and remote clinical trial operations during the COVID-19 Pandemic...
August 31, 2023: Gynecologic Oncology
Reem H Saab, Gloria Salvo, Naomi R Gonzales, Mark F Munsell, Eileen H Shinn, Anuja Jhingran, Priya Bhosale, Preetha Ramalingam, Michael Frumovitz
OBJECTIVE: Neuroendocrine cervical carcinoma (NECC) is rare. Educational resources are limited for NECC patients, leading many to seek information online through patient-led social networks. We sought to characterize the relationships between anxiety and depression levels and social media use among NECC patients. METHODS: Seven surveys assessing social media use, anxiety, and depression were distributed to living NECC patients enrolled in our NECC registry. The primary outcomes were associations between Social Network Time Use Scale (SONTUS) global score and Generalized Anxiety Disorder (GAD-7) and Center for Epidemiologic Studies Depression Scale (CESD) total scores...
August 30, 2023: Gynecologic Oncology
Dimitrios Nasioudis, Marta Llaurado Fernandez, Nelson Wong, Daniel J Powell, Gordon B Mills, Shannon Westin, Amanda N Fader, Mark S Carey, Fiona Simpkins
OBJECTIVE: To investigate the incidence of MAPK/ERK pathway genomic alterations among patients with gynecologic malignancies. METHODS: We accessed the American Association of Cancer Research Genomics Evidence of Neoplasia Information Exchange publicly available dataset (v13.0). Patients with malignant tumors of the ovary, uterus, and cervix were identified. Following stratification by tumor site and histology, we examined the prevalence of MAPK/ERK pathway gene alterations (somatic mutation, and/or structural chromosome alterations)...
August 30, 2023: Gynecologic Oncology
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.